{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:45:36Z","timestamp":1764402336496,"version":"3.40.5"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:p>BACKGROUND. The incidence of pertussis is increasing, especially in adolescents, attributed in part to waning of immunity after childhood immunization. Recently licensed in the United States for use in adolescents, acellular pertussis vaccines will provide an immunogenic and safe option for booster immunization against pertussis.<\/jats:p>\n               <jats:p>METHODS. This prospective, randomized, observer-blinded, multicenter, comparative study evaluated the safety and immunogenicity of a vaccine formulated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens (Tdap) compared with tetanus and diphtheria toxoids vaccine (Td) for booster immunization in adolescents. There were 4114 healthy adolescents aged 10 to 18 years who completed childhood vaccination against diphtheria, tetanus, and pertussis who were enrolled, randomized, and received study vaccine.<\/jats:p>\n               <jats:p>RESULTS. Local and general symptoms were comparable between the Tdap and Td groups. The immune response of Tdap was comparable with Td vaccine for tetanus and diphtheria seroprotection and booster responses. In addition, geometric mean concentrations of antibody to pertussis antigens, pertussis toxoid, filamentous hemagglutinin, and pertactin exceeded the antibody response elicited after infant immunization with diphtheria and tetanus toxoids and acellular pertussis antigens (DTaP) that had proven efficacy against pertussis.<\/jats:p>\n               <jats:p>CONCLUSIONS. In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants.<\/jats:p>","DOI":"10.1542\/peds.2005-1759","type":"journal-article","created":{"date-parts":[[2006,4,3]],"date-time":"2006-04-03T21:23:11Z","timestamp":1144099391000},"page":"1084-1093","source":"Crossref","is-referenced-by-count":60,"title":["Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents"],"prefix":"10.1542","volume":"117","author":[{"given":"Michael E.","family":"Pichichero","sequence":"first","affiliation":[{"name":"University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Blatter","sequence":"additional","affiliation":[{"name":"Primary Physicians Research, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"University of California Los Angeles Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hedrick","sequence":"additional","affiliation":[{"name":"Kentucky Pediatric Research, Inc, Bardstown, Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Rixensart, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"2021120902110976800_R1","unstructured":"Centers for Disease Control and Prevention. Pertussis: United States, 1997\u20132000. MMWR Morb Mortal Wkly Rep.\u20082002;51:73\u201376"},{"key":"2021120902110976800_R2","unstructured":"Centers for Disease Control and Prevention. Pertussis Surveillance Report: 8\/12\/05 (final data). Atlanta, GA: Bacterial Vaccine Preventable Diseases Branch, National Immunization Program, Centers for Disease Control and Prevention; 2005"},{"key":"2021120902110976800_R3","doi-asserted-by":"crossref","unstructured":"Gu\u0308ris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990\u20131996. Clin Infect Dis.\u20081999;28:1230\u20131237","DOI":"10.1086\/514776"},{"key":"2021120902110976800_R4","doi-asserted-by":"crossref","unstructured":"Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989\u20131998. J Infect Dis.\u20082000;182:1409\u20131416","DOI":"10.1086\/315863"},{"key":"2021120902110976800_R5","unstructured":"Sotir MJ, Cappazzo DL, Schmidt CE, et al. A resource and labor intensive county-wide outbreak of pertussis, Wisconsin, 2003: high impact on the adolescent population (abstract). Presented at: the 39th National Immunization Conference; March 21\u201324, 2005; Washington, DC"},{"key":"2021120902110976800_R6","doi-asserted-by":"crossref","unstructured":"Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995\u20131996. J Infect Dis.\u20082001;183:1353\u20131359","DOI":"10.1086\/319853"},{"key":"2021120902110976800_R7","doi-asserted-by":"crossref","unstructured":"Ward JI, Cherry JD, Chang S-J, et al, for the APERT Study Group. Efficacy of acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555\u20131563","DOI":"10.1056\/NEJMoa050824"},{"key":"2021120902110976800_R8","doi-asserted-by":"crossref","unstructured":"Wirsing von Ko\u0308nig CH, Postels-Multani S, Bogaerts H, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr.\u20081998;157:391\u2013394","DOI":"10.1007\/s004310050836"},{"key":"2021120902110976800_R9","doi-asserted-by":"crossref","unstructured":"Aoyama T, Harashima M, Nishimura K, Saito Y. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Paediatr Jpn.\u20081995;37:321\u2013324","DOI":"10.1111\/j.1442-200X.1995.tb03322.x"},{"key":"2021120902110976800_R10","doi-asserted-by":"crossref","unstructured":"Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B, and the Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis.\u20082001;32:1691\u20131697","DOI":"10.1086\/320754"},{"key":"2021120902110976800_R11","doi-asserted-by":"crossref","unstructured":"Hewlett EL, Edwards KM. Pertussis: not just for kids. N Engl J Med.\u20082005;352:1215\u20131222","DOI":"10.1056\/NEJMcp041025"},{"key":"2021120902110976800_R12","doi-asserted-by":"crossref","unstructured":"Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis.\u20082004;39:1572\u20131580","DOI":"10.1086\/425006"},{"key":"2021120902110976800_R13","doi-asserted-by":"crossref","unstructured":"Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med.\u20082000;9:989\u2013996","DOI":"10.1001\/archfami.9.10.989"},{"key":"2021120902110976800_R14","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med.\u20081997;151:35\u201340","DOI":"10.1001\/archpedi.1997.02170380039006"},{"key":"2021120902110976800_R15","doi-asserted-by":"crossref","unstructured":"Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J.\u20082005;24:S75\u2013S82","DOI":"10.1097\/01.inf.0000160918.72953.51"},{"key":"2021120902110976800_R16","doi-asserted-by":"crossref","unstructured":"Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis.\u20082004;39:20\u201328","DOI":"10.1086\/421091"},{"key":"2021120902110976800_R17","doi-asserted-by":"crossref","unstructured":"Wharton M. Prevention of pertussis among adolescents by vaccination: taking action on what we know and acknowledging what we do not know [editorial]. Clin Infect Dis.\u20082004;39:29\u201330","DOI":"10.1086\/421096"},{"key":"2021120902110976800_R18","doi-asserted-by":"crossref","unstructured":"Lee GM, LeBaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate?Pediatrics.\u20082005;115:1675\u20131684","DOI":"10.1542\/peds.2004-2509"},{"key":"2021120902110976800_R19","doi-asserted-by":"crossref","unstructured":"Forsyth KD, Campins-Marti M, Caro J, et al, for the Global Pertussis Initiative. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis.\u20082004;39:1802\u20131809","DOI":"10.1086\/426020"},{"key":"2021120902110976800_R20","doi-asserted-by":"crossref","unstructured":"Greco D, Salmaso S, Mastrantonio P, et al, and the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med.\u20081996;334:341\u2013348","DOI":"10.1056\/NEJM199602083340601"},{"key":"2021120902110976800_R21","doi-asserted-by":"crossref","unstructured":"Schmitt HJ, Wirsing von Ko\u0308nig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA.\u20081996;275:37\u201341","DOI":"10.1001\/jama.275.1.37"},{"key":"2021120902110976800_R22","unstructured":"Wassilak SGF, Roper MH, Murphy TV, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:745\u2013781"},{"key":"2021120902110976800_R23","unstructured":"Wharton M, Vitek CR. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:211\u2013228"},{"key":"2021120902110976800_R24","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee (day one). 1997. Available at: www.fda.gov\/ohrms\/dockets\/ac\/97\/transcpt\/3300t1.pdf Accessed April 5, 2005"},{"key":"2021120902110976800_R25","doi-asserted-by":"crossref","unstructured":"Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr.\u20081996;129:695\u2013701","DOI":"10.1016\/S0022-3476(96)70152-X"},{"key":"2021120902110976800_R26","doi-asserted-by":"crossref","unstructured":"Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis.\u20082003;14:196\u2013198","DOI":"10.1016\/S1045-1870(03)00033-5"},{"key":"2021120902110976800_R27","doi-asserted-by":"crossref","unstructured":"Woo EJ, Burwen DR, Gatumu SNM, Ball R, and the Vaccine Adverse Event Reporting System (VAERS) Working Group. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clin Infect Dis.\u20082003;37:351\u2013358","DOI":"10.1086\/375820"},{"key":"2021120902110976800_R28","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics.\u20081997;100:772\u2013786","DOI":"10.1542\/peds.100.5.772"},{"key":"2021120902110976800_R29","unstructured":"Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAP). MMWR Recomm Rep.\u20082002;51(RR-2):1\u201335"},{"key":"2021120902110976800_R30","unstructured":"Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep.\u20081991;40(RR-10):1\u201328"},{"key":"2021120902110976800_R31","doi-asserted-by":"crossref","unstructured":"Salmaso S, Mastrantonio P, Tozzi AE, et al, and the Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics.\u20082001;108(5). Available at: www.pediatrics.org\/cgi\/content\/full\/108\/5\/e81","DOI":"10.1542\/peds.108.5.e81"},{"key":"2021120902110976800_R32","doi-asserted-by":"crossref","unstructured":"McIntyre PB, Turnbull FM, Egan A-M, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine.\u20082004;23:380\u2013385","DOI":"10.1016\/j.vaccine.2004.05.030"},{"key":"2021120902110976800_R33","doi-asserted-by":"crossref","unstructured":"Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis.\u20082004;39:179\u2013185","DOI":"10.1086\/421943"},{"key":"2021120902110976800_R34","unstructured":"Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2005. MMWR Morb Mortal Wkly Rep.\u20082005;53:Q1\u2013Q3"},{"key":"2021120902110976800_R35","unstructured":"Kandola K, Lea A, Santos M. Pertussis rates in Northwest Territories after introducing adult formulation acellular vaccine [abstract]. Can J Infect Dis Med Microbiol.\u20082004;15:351."},{"key":"2021120902110976800_R36","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA.\u20082005;293:3003\u20133011","DOI":"10.1001\/jama.293.24.3003"},{"key":"2021120902110976800_R37","unstructured":"Advisory Committee on Immunization Practices. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine. Available at: www.cdc.gov\/nip\/pr\/pr_tdap_jun2005.htm. Accessed July 5, 2005"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1084\/1072161\/zpe00406001084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1084\/1072161\/zpe00406001084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T09:51:27Z","timestamp":1639043487000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/4\/1084\/70829\/Acellular-Pertussis-Vaccine-Booster-Combined-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,4,1]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1759","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}